Evidence map›Paper›PMID 40740337›Full record

ArticleFrontiers in microbiology2025

Incidence and risk factors of active carbapenem-resistant enterobacteriaceae surveillance in hematology patients: a propensity score matching study.

Shaozhen Chen, Jixin Fan, Tingting Xiao, Jinhua Ren, Haojie Zhu, Hui Kong, Dabing Chen, Jingjing Xu, Chenjing Ye, Jiaqi Sun and 7 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shaozhen Chen *The Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jixin Fan *The Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Tingting Xiao *Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Jinhua RenThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Haojie ZhuThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Hui KongThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Dabing ChenThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jingjing XuThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Chenjing YeDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Jiaqi SunDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Caidong HuThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xiaoyun ZhengThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Jing LiThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Xiaozhu YangThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Zhizhe ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Jianda HuDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Ting YangThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) infections pose a significant threat to hematological patients, contributing to high mortality rates. This retrospective study evaluated the incidence, risk factors, and patient outcomes associated with active CRE surveillance in the hematology department. Methods: The study identified 23,832 hematological patients between 2019 and 2021. Propensity score matching was used to align underlying diseases and admission times in a 1:1:1 ratio across three groups: detected CRE, undetected CRE, and non-active CRE surveillance. The positivity rate of active CRE surveillance was 2.1% (141/6,735), with an incidence of 4.8% (85/1,789) among patients who underwent active CRE surveillance. Results: The distribution of the 141 isolates was as follows: Discussion: The incidence of CRE infection was notably higher in the detected CRE group. Our study provides real-world evidence on the role of active CRE surveillance in survival outcomes, especially in regions like China, where CRE infections are highly prevalent. The findings suggest that active CRE surveillance could serve as an early indicator of 90-day mortality in hematology patients and should be considered for routine implementation in this population.

Indexed as

Carbapenem-resistant Enterobacteriaceaehematological diseasesincidencerisk factorsurveillance

Identifiers

PMID40740337
PMCPMC12307464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.